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Abstract
Background: While it is recognised that depression is prevalent in Rheumatoid Arthritis (RA), recent studies have
also highlighted significant levels of anxiety in RA patients. This study compared two commonly used scales, the
Depression Anxiety and Stress Scale (DASS) and the Hospital Anxiety and Depression Scale (HADS), in relation to
their measurement range and cut points to consider the relative prevalence of both constructs, and if prevalence
rates may be due to scale-specific case definition.
Methods: Patients meeting the criteria for RA were recruited in Leeds, UK and Sydney, Australia and asked to
complete a survey that included both scales. The data was analysed using the Rasch measurement model.
Results: A total of 169 RA patients were assessed, with a repeat subsample, resulting in 323 cases for analysis. Both
scales met Rasch model expectations. Using the ‘possible+probable’ cut point from the HADS, 58.3% had neither
anxiety nor depression; 13.5% had anxiety only; 6.4% depression only and 21.8% had both ‘possible+probable’
anxiety and depression. Cut points for depression were comparable across the two scales while a lower cut point
for anxiety in the DASS was required to equate prevalence.
Conclusions: This study provides further support for high prevalence of depression and anxiety in RA. It also
shows that while these two scales provide a good indication of possible depression and anxiety, the estimates of
prevalence so derived could vary, particularly for anxiety. These findings are discussed in terms of comparisons
across studies and selection of scales for clinical use.
Background
Rheumatoid Arthritis (RA) is a multifactorial, chronic,
inflammatory disease affecting primarily the joints with
prevalence of between 0.5%-1% [1]. Pain, fatigue and
disability, which may be considered as stress factors [2],
are common challenges that may subsequently lead to
psychological distress [3]. Depression commonly co-
occurs with RA, in the range of 13% to 20% [4] and
above [5] based on clinical assessments. Studies using
self report measures of depressive symptoms suggest
considerably higher rates (i.e. 40%), although the levels
of symptomatology may be subclinical [6]. Longitudinal
studies suggest cumulative risk for depression and inter-
mittent recurrence over time [i.e. 40% over 9 years; [7]].
The prevalence rates of depression in RA are well above
those reported in the general community or primary
care [8] but similar to other chronic conditions [9].
Depression in RA is associated with higher levels of dis-
ease activity, pain, fatigue, work disability, health service
use but lower treatment compliance [7,10] and increased
suicide risk [11,12] and mortality [7,13].
* Correspondence: t.covic@uws.edu.au
1School of Psychology, University of Western Sydney, Australia
Full list of author information is available at the end of the article
Covic et al. BMC Psychiatry 2012, 12:6
http://www.biomedcentral.com/1471-244X/12/6
© 2012 Covic et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Recent studies have also highlighted significant levels
(21% to 70%) of anxiety in RA [5]. While there is a con-
siderable overlap (i.e., 69% shared variance) between
anxiety and depression and the levels of anxiety are
higher when depression is present [14], the two are con-
s i d e r e dt ob ed i s t i n c t l ys e p a r a t ec o n s t r u c t s[ 1 5 ] .S o m e
studies report higher prevalence of anxiety than depres-
sion in RA [2,16], whereas others do not [5,17]. It is
likely that depression and anxiety influence RA via dif-
ferent mechanisms. A recent study found both to have a
direct effect on pain, although the direct effect of anxi-
ety was significantly higher than that of depression [18].
While anxiety appeared to increase exposure to stress,
only depression influenced pain via stress. According to
a tripartite model [15] it is possible that anxiety mani-
fests through physical arousal, increased sensitivity to
pain and/or interpretation of sensations as painful.
Depression, through the absence of pleasure, may
increase vulnerability to pain at times of stress [18] par-
ticularly amongst those with repeated episodes of major
depression [19]. This explanation is also consistent with
a stress process model which suggests that vulnerability
factors (such as anxiety and depression) may influence
exposure or reaction to stress [20]. Thus, while closely
linked, depression, anxiety and stress are proposed to be
distinct.
Given the importance of effective screening for
depression and anxiety in RA, it is essential to ensure
that they are being appropriately measured with avail-
able scales. Furthermore, it has been noted that the
rates of depression and anxiety vary considerably across
studies partly due to differences in assessment scales [5].
Those differences create difficulties in comparing results
across studies and, for clinicians, in interpreting with
confidence to what degree various scales may identify
those who are at risk for depression or anxiety and
require referral for further assessment [21].
To examine the degree to which measurements distin-
guish depression, anxiety and stress, the current study
sets out to co-calibrate two commonly used scales. The
Depression, Anxiety and Stress Scale [DASS; [22]] and
Hospital Anxiety and Depression Scale [HADS; [23]]
will be statistically mapped and compared in terms of
their construct independence and cut points. The DASS
was developed in response to concerns about the poten-
tial overlap between depression and anxiety [24], and to
independently measure a third factor, stress, which is
common to both of those constructs. The depression
and anxiety subscales of the DASS are reported to be
consistent with Clark and Watson’s [15] constructs of
low positive affect and physiological hyper-arousal,
although the correspondence of stress to their negative
affect construct is unclear [25]. Psychometric studies,
however, suggest that the DASS measures general
psychological distress while still maintaining some dis-
tinction between the three separate constructs [26]. A
number of factor analytic studies have examined the
structure of the DASS, and in general confirmed a
three-factor solution [e.g. [27]]. More recently however
those traditional methods have been supplemented with
modern techniques such as the Rasch measurement
model [28]. A recent study used Rasch analysis to assess
the short 21-item version of the DASS and found that
three items needed to be removed and two subscales,
anxiety and stress, appear to measure a single underly-
ing construct [29].
The HADS has been extensively evaluated across
various somatic, psychiatric and primary care popula-
tions [30] and more recently, musculoskeletal [31],
cancer [32], end stage renal disease [33] and RA [21]
and found to distinctly measure depression and anxiety
with two, seven-item subscales. The HADS was specifi-
cally developed for use in primary or secondary health
settings to exclude somatic items that may be reflective
of the context (i.e. physical condition). It provides a
well-established, valid and reliable measure for com-
parison to the DASS. Both scales have been tested in
terms of their screening ability and cut points against
commonly accepted diagnostic gold standard such as
the Diagnostic and Statistical Manual [33-35]. It is,
however, recognised that detection of psychiatric con-
ditions such as depression and anxiety is complicated
by the comorbidity of physical conditions even when
using diagnostic interviews based on DSM or ICD,
unless modified [36,37]. For the purpose of this study
HADS will be considered as an interim gold standard
as it has been extensively validated across somatic and
psychiatric populations in primary care and the general
community [30] and is recommended for use in the
physically ill [37].
By co-calibrating the items from both scales onto a
single metric the three constructs, depression, anxiety
and stress, will be mapped to: (a) compare the range of
DASS depression and anxiety to that of the HADS
scales; and (b) compare the two scales’ cut points for
depression and anxiety to determine if any variability
may be due to scale-specific case definition.
Methods
Patients and setting
DASS and HADS item responses were obtained from
patients attending the Yorkshire Early Arthritis Register
(YEAR) clinic in Leeds, UK (n = 89) and private and
hospital clinics in Sydney, Australia (n = 80). All partici-
pants met RA diagnosis. Ethical approval was granted by
the NHS York Research Ethics Committee, UK (Ref 07/
Q1108/25) and the University of Western Sydney
Human Ethics Committee, Australia (ref no H5417).
Covic et al. BMC Psychiatry 2012, 12:6
http://www.biomedcentral.com/1471-244X/12/6
Page 2 of 10Participants’ written consent was obtained in accordance
with the Declaration of Helsinki.
Measurements
In addition to demographic data, the following scales
were included in the study:
Depression Anxiety Stress Scales (DASS)
The Depression Anxiety Stress Scales (DASS) is a 42-
item self-report measure of depression, anxiety and
stress [22]. It consists of three 14-item subscales with
each item scored on a 4-point Likert scale, ranging from
0( did not apply to me at all)t o3( applied to me very
much, or most of the time). Total scores are calculated
by summing the items on each subscale, giving a score
range of 0-42 on each subscale. Scores above 20, 14 and
25 on the depression, anxiety and stress subscales
respectively are indicative of severe levels [22]. The
DASS shows good convergent and discriminant validity,
and high internal consistency and reliability, with Cron-
bach’s alpha reported at 0.94 for Depression, 0.87 for
Anxiety and 0.91 for Stress [34].
Hospital Anxiety and Depression Scale (HADS)
The Hospital Anxiety and Depression Scale [HADS;
[23]] is designed to measure both anxiety and depres-
sion in out-patient populations. Each subscale comprises
seven items which are rated on a four-point scale and
scored from 0-3 with total scores therefore ranging
from 0-21 for each subscale. Scores between 0 and 7
represent ‘no case’; 8 to 10 indicate ‘possible case’ and
11 to 21 suggest a ‘probable case of anxiety/depression’.
These cut points have been validated against clinical
interviews with sensitivity and specificity around 0.80
[30]. Recent studies have reported good internal consis-
tency for both anxiety (0.89) and depression (0.86) sub-
scales [38].
Rasch Analysis
Rasch analysis is a process to test if a set of data
intended to be summated to give a total score satisfies
the rules for constructing interval scale measurement
[39]. The process involves a number of tests to see if
the data meet the Rasch model assumptions. These
include a probabilistic relationship between items (sto-
chastic ordering); local independence and unidimension-
ality. The analytical framework also enables checking to
see if the scale works in the same way across groups
(invariance as determined by Differential Item Function-
ing-DIF) and examining the reliability and targeting of
the scale to the sample. In the context of health out-
come measurement the process is described in detail
elsewhere [31,40,41].
The process of Rasch analysis is essentially one of test-
ing the above assumptions. Briefly, fit (stochastic order-
ing) to the Rasch model is achieved when summary and
individual item chi-square statistics are non-significant,
showing no deviation from model expectation (Bonfer-
roni adjusted); where item and person summary fit sta-
tistics show a mean of zero and standard deviation of 1,
and where individual item and person residuals are
within the range of +/- 2.5.
The assumption of local independence of the item set
is verified by the absence of correlations above 0.3
among the residuals of the items tests. Where this
assumption is violated and local dependency is found,
items can be grouped together in the form of ‘testlets’,
which absorbs the impact of local dependency [42]. The
items within each subscale (e.g. depression) can also be
grouped together as a testlet and treated as a ‘super
item’ or ‘higher order item’ [43]. This enables a detailed
examination of the relationships between subscales,
including the unique component of each scale, the sum-
mary correlation between subscales, corrected for
attenuation, and the common variance of the total score
(adding together all domains assuming unidimensional-
ity) relative to the common and unique variance (i.e.
total variance). A high common variance (e.g. 0.9 and
above) would indicate that the various subscales were,
in general, mapping onto a higher order construct and
were correlated sufficiently highly that the total score
obtained by summating all subscales together sum-
marizes the profile of the majority of persons [43]. This
co-calibration approach also enables a comparison of
the operational range of the various subscales, which is
one of the aims of the current study.
The test for the assumption of unidimensionality is
that described by Smith [44]. Here two estimates are
derived from different subsets of items identified by
their loading on the first principal component of the
residuals. The estimates are compared and when less
than 5% are significantly different this supports
unidimensionality.
In addition, the scale is expected to show invariance
across key groups (e.g. gender or age), as indicated by a
non-significant two-way ANOVA of the residuals where
group is one factor, and (in this case) the level of psy-
chological distress, a second factor. The latter is deter-
mined by simply grouping respondents by their level of
distress using the raw score. Reliability indices are also
calculated, namely, Cronbach’s Alpha and the Person
Separation Index (PSI).
The Rasch analysis was conducted using RUMM2030
software [45].
Results
Descriptive
In total 169 RA patients were assessed in both countries,
and with repeated clinic attendances in the UK, 323
assessments in total were available. The recruitment was
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with the UK data (n = 89) representing early RA (dura-
tion < 2 years), and the Australian data (n = 80) more
established disease, (mean duration = 13.36, SD =
11.17). However, there were no significant differences in
age between the two samples (mean age = 58.3 years,
SD = 15.1, p >.05), nor a difference in gender (Chi
Square 0.059; p = 0.86). For analytical purposes these
data were separated into two samples, the initial baseline
data of 169 assessments (73% of whom were female),
and follow-up data from the UK of 154 repeated assess-
ments (based on two further data collection points).
The mean scores and proportions according to cut
points for depression, anxiety and stress (DASS) and
depression and anxiety (HADS) are shown in Table 1.
While overall mean scores were low across the three
subscales on the DASS, 8.3% of the sample recorded
scores in the ‘severe’ or ‘extremely severe’ range for
depression, 7.8% for anxiety and 9.8% for stress. On the
HADS, 9.4% of the sample were classified as a ‘probable
case’ of depression (scores 11+) and 18.6% as a ‘probable
case’ of anxiety (scores 11+). Using the ‘possible+prob-
able’ cut point (scores 8+) from the HADS, 58.3% had
neither anxiety nor depression; 13.5% had anxiety only;
6.4% depression only, and 21.8% had both ‘possible
+probable’ anxiety and depression.
Rasch Analysis
Generally all subscales were consistent with Rasch
model expectations, Fit of the baseline data of the indi-
vidual subscales of the DASS and the HADS, and the
various combinations, including the final testlet based
v e r s i o na r es h o w ni nT a b l e s2& 3 .T h eD A S S - A n x i e t y
subscale showed initial fit to the model (Table 2, Analy-
sis 1), but improved further after some items were
rescored (Analysis 2), and local dependency was
adjusted by testlets (Analysis 3). The HADS-Anxiety
subscale showed good fit at the outset (Analysis 4). All
solutions showed strict unidimensionality and local
independence. All were free of DIF by age, gender and
country. When both the DASS and HADS anxiety items
were combined some misfit was observed, and some
multidimensionality (Analysis 5). Although creating test-
lets to accommodate local dependency improved fit
(analysis 6), two locally dependent items from the
HADS required removal to obtain a strictly unidimen-
sional solution (Analysis 7).
The depression subscales showed good fit to the
Rasch model, and only the DASS set of items needed
adjustment for local dependency (Table 3, Analyses 8
and 9), whereas the HADS-Depression subscale satisfied
model expectations from the outset (Analysis 10). All
solutions were free of DIF, strictly unidimensional and
locally independent. When all items were pooled
together, some slight misfit was observed (Analysis 11),
but this resolved after creating testlets to accommodate
local dependency (Analysis 12). The DASS-Stress sub-
scale also satisfied model expectations at the outset
(Analysis 13).
When all subscales were treated as testlets (making
f i v es u p e ro rh i g h e ro r d e ri t e m si nt o t a l ) ,f i tt ot h e
Rasch model supported unidimensionality of the com-
mon latent construct (Analysis 14). The ratio of unique
to total non-error variance was high (0.97). Replication
was then conducted on the repeated assessment sample
(n = 153, UK only) to confirm this interpretation (Ana-
lysis 15). The ratio of unique to total variance on this
occasion was 0.93, supporting the interpretation that all
subscales map on to a common underlying higher-order
construct.
The five testlets (i.e. the three DASS subscales and the
two HADS subscales, consisting of all items and in their
original scoring version) were then mapped, allowing
comparison of their operational ranges (Figure 1).
This logit based metric has been rescaled from 0-25
for ease of interpretation, the width of which was deter-
mined by a combination of the HADS-Anxiety subscale,
which had the lowest level on the common metric (so
giving a score of zero), and the DASS-Anxiety subscale
which had the highest level on the metric (so giving a
Table 1 Prevalence of Stress, Anxiety and Depression according to HADS and DASS (n = 169)
Scale Mean SD Possible (H)/Mild & Moderate
(D)
(%)
Probable(H)/
Severe & Extremely Severe
(D)
(%)
Poss/Prob(H)
Mild, Moderate, Severe/Extremely Severe
(D)
(%)
Depression
(DASS)
6.94 9.22 17.2 8.3 25.5
Depression
(HADS)
5.10 4.00 18.9 9.4 28.3
Anxiety (DASS) 5.32 8.01 19.5 7.8 27.3
Anxiety (HADS) 5.97 4.82 16.7 18.6 35.3
Stress (DASS) 9.17 10.49 8.5 9.8 18.3
62.6re/Extreme ut points. ne, with proportions within each actegory. the majoroty that such estimates would be ammenable H = HADS; D = DASS (columns
subject to rounding)
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points of the HADS subscales are shown, along with the
‘mild’ to ‘extremely severe’ cuts points for the DASS.
The HADS-Anxiety subscale has the widest operational
r a n g e( 2 2 . 1 8o nt h ec o m m o nm e t r i c ) ,a n dt h eD A S S -
Depression subscale the narrowest range (10.61 on the
common metric). The cut point for ‘extremely severe’
on the DASS-Stress subscale is the highest on the con-
struct (so giving the lowest prevalence), followed by the
‘extremely severe’ cut point for the DASS-Anxiety sub-
s c a l e( T a b l e4 ) .T h eH A D S - A n x i e t y‘possible’ cut point
is the lowest on the common underlying metric, and
thus associated with the highest prevalence, giving
35.3% of patients falling above this cut (including the
‘probable’ patients).
The HADS-Depression ‘probable’ cut point and the
DASS-Depression ‘severe’ and ‘extremely severe’ cut
point gave levels of prevalence for depression of a simi-
lar magnitude, and are closely located on the underlying
metric. However, there is considerable difference in
terms of HADS-Anxiety ‘probable’ when contrasted with
the DASS-Anxiety ‘severe’ and ‘extremely severe’ cut
points, with the prevalence on the HADS-Anxiety more
than double that of the prevalence on DASS-Anxiety.
This is consistent with the ‘probable’ cut point on the
HADS-Anxiety being lower on the common metric than
the DASS-Anxiety ‘severe’ cut point, thus generating a
higher prevalence. However, if the DASS-Anxiety ‘mild’
cut point is included, then prevalence is similar, with
the ‘mild’ DASS-Anxiety cut point being at a similar
location to the HADS-Anxiety ‘possible’ cut point (Fig-
ure 1).
Given the metric, it is possible to provide ‘exchange’
rates between the respective subscales of the two scales.
For example, the ‘probable’ cut point of the HADS-
Depression subscale of 11 po i n t si se q u i v a l e n tt o2 7
points on the DASS-Depression subscale, which is the
highest score within its ‘moderate’ range (Figure 2).
Likewise the HADS-Anxiety ‘probable’ cut point of 11
is equivalent to a score of 14 on the DASS-Anxiety
Table 2 Fit of the DASS-Anxiety and HADS-Anxiety items to the Rasch model
Analysis Subscale Item Fit Residual Person Fit Residual Chi-Square Interaction PSI Uni-dimensionality
Mean SD Mean SD Value DF P % tests CI
Anxiety
1 DASS-A -0.464 1.385 -0.308 0.945 48.21 28 0.010 0.863 6.63 3.3-9.9
2 DASS-A -0.371 1.352 -0.272 0.970 36.90 28 0.121 0.860 5.42 2.1-8.7
3 DASS-A -0.219 0.790 -0.267 1.016 16.48 20 0.686 0.839 1.81 -1.5-5.1
4 HADS-A -0.026 1.509 -0.296 1.088 23.09 14 0.588 0.838 2.41 -0.1-5.7
Anxiety Combined
5 D+H-A -0.301 1.418 -0.287 1.067 79.648 42 0.0004 0.892 8.38 5.1-11.7
6 D+H-A -0.152 1.084 -0.296 1.107 42.17 34 0.158 0.880 9.58 6.3-12.9
7 D+H-A -0.218 1.019 -0.305 1.046 37.11 32 0.245 0.871 4.79 1.5-8.1
Ideal Fit 0.0 1.0 0.0 1.0 > 0.05* > 0.7 < 5.0 Lower CI below 5
*Bonferroni adjusted
Table 3 Fit of the DASS and HADS items and all subscales (testlets) to the Rasch model
Analysis Subscale Item Fit Residual Person Fit Residual Chi-Square Interaction PSI Uni-dimensionality
Mean SD Mean SD Value DF P % tests CI
Depression
8 DASS-D -0.396 1.541 -0.431 1.244 49.69 28 0.007 0.945 6.59 3.3-9.9
9 DASS-D -0.276 1.567 -0.354 1.132 39.34 22 0.013 0.940 4.79 1.5-8.1
10 HADS-D -0.263 0.872 -0.382 0.899 25.16 28 0.619 0.856 3.01 0.0-6.3
Depression Combined
11 D+H-D -0.560 1.422 -0.442 1.133 68.82 42 0.005 0.920 12.05 8.7-15.4
12 D+H-D -0.423 1.248 -0.373 1.084 57.31 34 0.007 0.912 7.23 3.9-10.5
Stress
13 DASS-S -0.025 1.383 -0.425 1.575 41.18 28 0.052 0.949 7.19 3.9-10.5
All Scales combined as testlets
14 All -0.400 0.729 -0.353 0.842 10.73 10 0.378 0.900 2.52 0.0-5.9
15 All -0.123 0.749 -0.378 0.968 10.12 10 0.430 0.870 2.00 -1.5-5.5
Ideal Fit 0.0 1.0 0.0 1.0 > 0.05* > 0.7 < 5.0 Lower CI below 5
*Bonferroni adjusted
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level. A score of 20 on the DASS-Anxiety subscale
(extremely severe) is equivalent to a score of 13 (’prob-
able’) on the HADS-Anxiety subscale.
Finally, irrespective of the differential raw scores asso-
ciated with the various severity-specific cut points on
the DASS subscales (e.g. at extremely severe) all sever-
ity-specific cut points are shown to map onto a similar
point on the underlying metric. That is, the DASS
‘extremely severe’ cut points for anxiety and depression
mark the same location on the underlying metric, as do
the ‘severe’ cut points. It follows from this that the pre-
valence of the two constructs as defined by the DASS
do not vary greatly. The ‘extremely severe’ cut point for
the DASS-Stress subscale is the highest on the metric,
as is its ‘mild’ cut point, compared with the other
DASS’s subscales, so giving a lower prevalence asso-
ciated with each cut point.
Discussion
Depression and anxiety frequently occur in RA. This
study compared two commonly used screening scales,
HADS and DASS, in relation to their measurement
range and cut points to consider if prevalence rates may
be due to scale-specific case definition.
The individual subscales of depression and anxiety
(HADS and DASS) and stress (DASS only) showed a
good fit to Rasch model expectations. After some
adjustments to the ordering of thresholds and for local
dependency for the DASS Anxiety and Depression sub-
scales, interval scale transformation was achieved for all
 
Figure 1 Operational ranges and cut points of the DASS/HADS subscales.
Table 4 Hierarchy of various cut points on the common
metric*
Scale Level Magnitude
DASS-Stress Extremely Severe 17.16
DASS-Anxiety Extremely Severe 16.65
DASS-Depression Extremely Severe 16.52
HADS-Depression Probable 16.39
DASS-Stress Severe 16.07
DASS-Anxiety Severe 15.88
DASS-Depression Severe 15.68
HADS-Anxiety Probable 15.68
DASS-Stress Moderate 15.04
DASS-Anxiety Moderate 14.78
DASS-Depression Moderate 14.66
HADS-Depression Possible 14.53
DASS-Stress Mild 14.27
DASS-Anxiety Mild 14.08
DASS-Depression Mild 13.88
HADS-Anxiety Possible 13.82
* Scale Ranges: DASS-Stress 5.99-20.83; DASS-Anxiety 7.01-25.0; DASS-
Depression 9.13-19.73; HADS-Anxiety 0.0-22.18; HADS-Depression 2.83-24.62.
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HADS Anxiety subscales required some modifications to
create a unidimensional scale whereas only minor
changes were necessary to merge DASS Depression and
HADS Depression. This suggests that the anxiety sub-
scales across the two scales may measure different
a s p e c t so ft h i sc o n s t r u c t .T h i sf i n d i n gh a si m p l i c a t i o n s
for interpretation of anxiety rates across studies and the
selection of anxiety scales. It is important to further
investigate the clinical relevance of those scales.
When, however, all subscales were mapped together as
testlets, they were found to measure a common underly-
ing trait. This is consistent with the testlet design, when
used in this fashion, being equivalent to the bi-factor
model, where all sub-domains load onto one common
domain, while unique components load on to secondary
domains [46]. In this instance it was found that the
unique variance was low, and that the majority of var-
iance was shared by the five subscales. This finding may
be due to the use of testlets, as in removing local depen-
d e n c yt h o s et e s t l e t sm a ya l s or e m o v es o m ed i s c r e t e
uniqueness within each subscale (which when individu-
ally tested all met Rasch analysis expectations). It may
also be due to an overlap between the two constructs,
depression and anxiety, either as a result of their
measures assessing general distress [14] to a degree, or
that they may in fact be demonstrating their share com-
mon causal factors [47]. Nonetheless, the two constructs
are seen as distinctly different, anxiety being motivated
by fear while depression by sadness [48]. Finally, the
commonality detected may also be due to a high level of
comorbidity of depression and anxiety in this study’s
sample. This comorbidity is particularly significant given
its occurrence in the context of a physical comorbidity
(RA). It highlights the clinical complexity and associated
implications for the treatment of both depression and
anxiety in the presence of the physical manifestations of
RA. It is also important that further research explores
the structure of depression and anxiety constructs in
relation to their common underlying construct of psy-
chological distress.
Irrespective of the derivation of the cut points, it was
possible through the common metric provided by Rasch
analysis, to compare DASS cut points with those of the
HADS. Depending upon which cut points were chosen,
prevalence estimates could be similar. For example, the
HADS ‘probable’ and DASS ‘extremely severe’ cut points
for depression were found to be closely matched. For
anxiety, however, comparable cut points were only
f o u n da tal o w e re n d .T h a ti s ,t h eD A S S - A n x i e t y‘mild’
 
Figure 2 Co-calibration of HADS ‘Probable’ Depression Cut Point (1) with DASS. Read a score of 11 across to the HADS line (1); then read
up to the DASS line (2), and then read back to the raw score, which in this example shows 27 (Rounded).
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ble’ and above cut point. The DASS-Anxiety ‘extremely
severe’ cut point was higher on the construct than the
HADS-Anxiety ‘probable’ cut point. This may be due to
t h ed i f f e r e n c ei nf o c u so ft h ea n x i e t yi t e m s ,w i t ht h e
DASS reflecting feelings of panic and physical symptoms
(e.g. dryness of mouth) while the HADS subscale was
developed to exclude somatic symptoms and is closely
aligned with the generalised anxiety disorder [38]. This
is an important finding suggesting that these anxiety
scales need further clinical verification to determine
which aspects of anxiety they measure, and their con-
cordance with clinical diagnostic assessments.
As such, these findings have important implications
for screening and interpretation of research findings
across studies. First, this study supports previous find-
ings that elevated levels of both depression and anxiety
occur in RA [i.e. [5]]. Second, it permits a direct com-
parison of the ability of these two measures to distin-
guish between depression and anxiety, and their derived
estimates of prevalence. The operational ranges of mea-
surement between the scales were found to vary and the
cut points needed combined calibration in order to
determine appropriate comparability.
The DASS cut points were originally determined by
distributional difference of their norming sample, later
confirmed in clinical populations [34,49,50]. However, in
the current study an interesting observation is that the
severity-specific DASS cut points for the anxiety and
depression subscales all appeared to measure the same
point on the underlying metric, irrespective of the speci-
fic construct they represent, giving almost identical pre-
valence for depression and anxiety. In contrast, this was
not the case for the HADS. This similarity for DASS cut
points requires further investigation.
The study has a number of limitations. Although both
scales have previously been evaluated against clinical
diagnostic assessment [34,51] it is not possible to deter-
mine which one may do so with more specificity/sensi-
tivity in this study. The study was also restricted to RA
population, and it would be useful to see if the same
results were to be found in other rheumatic diseases
given that it is not clear to what degree depression and
anxiety presentation and severity may vary across other
rheumatic conditions. While the study was not designed
to look at responsiveness of these scales, it has shown
that their structures are invariant across countries (UK
and Australia) and time (examined in UK only). This is
an essential requirement for future studies to assess
responsiveness of those scales.
In conclusion, the current study highlights the comor-
bidity of anxiety and depression with RA. It also high-
lights the challenges of measuring depression and
anxiety given the limitations of assessment measures,
and the complexity of those conditions. However, this
study shows that at least some confusion can be
addressed with a co-calibration of depression and anxi-
ety screening scales to enable the comparison of the
estimates across scales and studies. That is, the results
for the two scales compared in this study suggest that
for depression a comparison between the ‘probable’
category on the HADS and ‘extremely severe’ on the
DASS may be made, but that for anxiety, a comparison
of DASS ‘mild’ and HADS ‘possible’ is better aligned.
This study also highlights the importance of developing
a common metric upon which all scales, and their cut
points, may be calibrated.
Conclusions
The authors envisage three key implications from these
findings. First, researchers investigating the prevalence
of psychological distress amongst people with RA need
to be mindful of the lack of concordance of the cut
points across scales, and the impact this may have on
prevalence estimates and meta-analytic studies. Second,
this study reasserts the high rates of depression in RA
patients and the need for regular assessment in both
early and established RA. This is pertinent given the
close association between depression and pain [52] and
health outcomes in RA. Third, this study further sub-
stantiates converging evidence of the high rates of symp-
toms of anxiety amongst people with RA. Risk factors
for anxiety, unlike for depression, are yet to be systema-
tically examined in relation to RA [53].
In terms of immediate clinical application, screening
scales such as HADS and DASS provide a good indica-
tion of possible depression and anxiety and may be used
for regular screening of psychological distress. It is how-
ever, important to understand that those scales may not
measure quite the same levels or aspects of that psycho-
logical distress, particularly so in relation to anxiety.
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